Form 8-K - Current report:
SEC Accession No. 0000950170-25-044783
Filing Date
2025-03-26
Accepted
2025-03-26 07:38:40
Documents
12
Period of Report
2025-03-26
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K mreo-20250326.htm   iXBRL 8-K 51872
2 EX-99.1 mreo-ex99_1.htm EX-99.1 225940
  Complete submission text file 0000950170-25-044783.txt   457410

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT mreo-20250326.xsd EX-101.SCH 58315
15 EXTRACTED XBRL INSTANCE DOCUMENT mreo-20250326_htm.xml XML 6519
Mailing Address ONE CAVENDISH PLACE FOURTH FLOOR LONDON X0 W1G0QF
Business Address ONE CAVENDISH PLACE FOURTH FLOOR LONDON X0 W1G0QF 4403330237300
Mereo BioPharma Group plc (Filer) CIK: 0001719714 (see all company filings)

EIN.: 000000000 | State of Incorp.: X0 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38452 | Film No.: 25770194
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)